Agriline
VC Fund
Bromsgrove, United Kingdom
Agriline is a VC fund in Bromsgrove focused on Health Care and Medical. Agriline is the investment vehicle owned by a trust of which Trendlines' controlling shareholder Vincent Tchenguiz.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Agriline invests in
Health CareMedicalMedical DeviceBiotechnologyAgTech
Stages Agriline invests in
SeedSeries AVenture - Series UnknownFunding RoundDebt Financing
Countries Agriline invests in
Israel
Round sizes
Seed $1.3M–$7.5MSeries A $5M–$17MVenture - Series Unknown $2.2M–$16M
Round size
- Seed
- $1.3M–$7.5M
- Series A
- $5M–$17M
- Venture - Series Unknown
- $2.2M–$16M
Investment Focus
Industry
- Health Care 6 (40%)
- Medical 4 (27%)
- Medical Device 4 (27%)
- Biotechnology 3 (20%)
- AgTech 2 (13%)
Stage
- Seed 5 (33%)
- Series A 4 (27%)
- Venture - Series Unknown 4 (27%)
- Funding Round 1 (7%)
- Debt Financing 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vessi Medical
|
Vessi Medical, an Israeli medical device startup, brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). Vessi uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, requiring a costly hospital stay performed under general anesthesia, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life.Vessi's minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The company's patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT, reducing the need for hospital stay by providing in office or ambulatory treatment. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. | $16.5M / Series A / Feb 14, 2024 | |
Phytolon
|
Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability | $14.5M / Series A / Jul 05, 2022 | |
SetBone Medical
|
SetBone Medical develops a new bone cement for the treatment of VCF and primarily caused by osteoporosis. | $1.6M / Debt Financing / Jan 26, 2022 | |
FruitSpec
|
FruitSpec provides yield estimation as a service. They come, they scan the orchard, and provide the reports. FruitSpec provides two types of report: The first report gives the number of fruits and the size distribution in a specific orchard. The second report uses a heat-map to show the distribution of fruit quantities in that orchard. | $5M / Series A / Nov 16, 2021 | |
Vensica Medical
|
Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%).Using Vensica’s device, the drug will be instilled in a quick, pain-free proceduresubsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates. | $16M / Venture - Series Unknown / Nov 01, 2021 | |
Fidmi Medical
|
Fidmi Medical is an Israeli start-up company founded in 2014 that is dedicated to developing enhanced feeding devices that offer easy insertion, replacement, and removal. | $2.2M / Venture - Series Unknown / Oct 11, 2021 | |
CoreBone
|
CoreBone has developed a highly bioactive, 100% mineral, strong bone graft material for dental, orthopedic and spine applications. The patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals during their growth process, accelerating healing and providing better bone connectivity. CoreBone was founded by CEO OhadSchwartz and CTO Prof. Itzhak Binederman. It is one of the portfolio companies of The Trendlines Group. CoreBone has issued patents and substantial know-how in regard to growing coral for medical purposes. | $3.7M / Venture - Series Unknown / Oct 04, 2021 | |
AgroScout
|
AgroScout is developing an autonomous system that allows for quick and efficient detection and monitoring of specific diseases in an entire field.The AgroScout system combines data from multiple sensors (covering an entire field); external data from weather, satellite, local sensors; machine learning; and deep learning to accurately andautonomously detect, identify, and monitor diseases in the field. This data will be analyzed by AgroScout’s algorithms to detect and identify disease and pests. The resulting data will be uploaded to the cloud, and farmers will receive actionable insights on their computer or mobile phone notifying them of disease location and status, with recommendations for treatment. | $7.5M / Series A / Aug 04, 2021 | |
|
AgroScout
|
AgroScout is developing an autonomous system that allows for quick and efficient detection and monitoring of specific diseases in an entire field.The AgroScout system combines data from multiple sensors (covering an entire field); external data from weather, satellite, local sensors; machine learning; and deep learning to accurately andautonomously detect, identify, and monitor diseases in the field. This data will be analyzed by AgroScout’s algorithms to detect and identify disease and pests. The resulting data will be uploaded to the cloud, and farmers will receive actionable insights on their computer or mobile phone notifying them of disease location and status, with recommendations for treatment. | $7.5M / Seed / Aug 04, 2021 | |
IBI-Ag
|
IBI-Ag is a biotechnology company developing a new class of bioinsecticides. IBI-Ag is focused on the discovery and development of new types of biological solutions that utilize environmentally friendly technology to control insects. IBI-Ag utilizes breakthrough technology to produce efficient, selective, and safe bio-insect control solutions.IBI-Ag technology is highly cost-effective due to its fermentation suitability enabling farmers to produce agricultural produce at a low cost. | Seed / Jun 21, 2021 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Agriculture (agtech) Investors
10,346 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
FAQ
What does Agriline invest in?
Agriline invests primarily in Health Care, Medical and Medical Device startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Agriline's check size?
Agriline typically joins rounds of $1.3M–$7.5M at Seed, $5M–$17M at Series A and $2.2M–$16M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Agriline participates in.
When did Agriline last invest?
The most recent investment recorded for Agriline closed in Feb 2024. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
